Journal of Biological Chemistry · 2012 · 17 citations · 28 references
MedicineCell BiologyOncologyCell SignalingMetastasisSignal TransductionCancer Cell SignalingCell Surface Receptor SignalingMetastatic Signaling PathwaysSignal Transduction In CancerCancer Metastasis MechanismsCancer Signaling PathwaysFas LigandMetastatic MechanismsMetastatic SignalingStat3 SignalingTumor Cell MotilityTumor Metastasis Biology
Many late-stage cancer cells express Fas ligand (FasL) and show high malignancy with metastatic potential. We report here a novel signaling mechanism for FasL that hijacks the Met signal pathway to promote tumor metastasis. FasL-expressing human tumor cells express a significant amount of phosphorylated Met. The down-regulation of FasL in these cells led to decreased Met activity and reduced cell motility. Ectopic expression of human FasL in NIH3T3 cells significantly stimulated their migration and invasion. The inhibition of Met and Stat3 activities reverted the FasL-associated phenotype. Notably, FasL variants activated the Met pathway, even though most of their intracellular domain or Fas binding sites were deleted. FasL interacted with Met through the FasL(105–130) extracellular region in lipid rafts, which consequently led to Met activation. Knocking down Met gene expression by RNAi technology reverted the FasL-associated motility to basal levels. Furthermore, treatment with synthetic peptides corresponding to FasL(117–126) significantly reduced the FasL/Met interaction, Met phosphorylation, and cell motility of FasL+ transfectants and tumor cells. Finally, the transfectants of truncated FasL showed strong anchorage-independent growth and lung metastasis potential in null mice. Collectively, our results establish the FasL-Met-Stat3 signaling pathway and explains the metastatic phenotype of FasL-expressing tumors. Many late-stage cancer cells express Fas ligand (FasL) and show high malignancy with metastatic potential. We report here a novel signaling mechanism for FasL that hijacks the Met signal pathway to promote tumor metastasis. FasL-expressing human tumor cells express a significant amount of phosphorylated Met. The down-regulation of FasL in these cells led to decreased Met activity and reduced cell motility. Ectopic expression of human FasL in NIH3T3 cells significantly stimulated their migration and invasion. The inhibition of Met and Stat3 activities reverted the FasL-associated phenotype. Notably, FasL variants activated the Met pathway, even though most of their intracellular domain or Fas binding sites were deleted. FasL interacted with Met through the FasL(105–130) extracellular region in lipid rafts, which consequently led to Met activation. Knocking down Met gene expression by RNAi technology reverted the FasL-associated motility to basal levels. Furthermore, treatment with synthetic peptides corresponding to FasL(117–126) significantly reduced the FasL/Met interaction, Met phosphorylation, and cell motility of FasL+ transfectants and tumor cells. Finally, the transfectants of truncated FasL showed strong anchorage-independent growth and lung metastasis potential in null mice. Collectively, our results establish the FasL-Met-Stat3 signaling pathway and explains the metastatic phenotype of FasL-expressing tumors.
28
Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand
Tomohiro Takahashi, Masato Tanaka, Camllynn I. Brannan et al. · Cell · 1994 · 1.5K citations
Life Sciences, Immunology, Pathology +12
Signaling networks assembled by oncogenic EGFR and c-Met
Ailan Guo, Judit Villén, Jon M. Kornhauser et al. · Proceedings of the National Academy of Sciences · 2008 · 505 citations · Full text
The Role of Fas in Autoimmune Diabetes
Alexander V. Chervonsky, Yi Wang, F. Susan Wong et al. · Cell · 1997 · 500 citations · Full text